Abstract
This brief communication reports on a patient with an exceedingly rare "8p11 (eight-p-eleven) myeloproliferative syndrome" (EMS) with CEP110-FGFR1 rearrangement who responded to treatment with the multi-tyrosine kinase inhibitor (TKI) dasatinib. Dasatinib improved quality of life substantially by increasing blood counts and reducing the need for transfusions. This report demonstrates that the second-generation TKI may provide a therapeutic option for elderly and frail EMS patients who cannot be offered aggressive therapy, including allogeneic hematopoietic cell transplantation. The Oncologist 2017;22:480-483.
Keywords:
Acute myeloid leukemia; CEP110‐FGFR1 fusion protein; Dasatinib; Eosinophilia; Imatinib.
© AlphaMed Press 2017.
MeSH terms
-
Cell Cycle Proteins / genetics*
-
Chromosomes, Human, Pair 8 / genetics
-
Dasatinib / administration & dosage
-
Down Syndrome / drug therapy*
-
Down Syndrome / genetics
-
Down Syndrome / pathology
-
Female
-
Humans
-
Leukemoid Reaction / drug therapy*
-
Leukemoid Reaction / genetics
-
Leukemoid Reaction / pathology
-
Middle Aged
-
Neoplasms / drug therapy*
-
Neoplasms / genetics
-
Neoplasms / pathology
-
Oncogene Proteins, Fusion / genetics
-
Protein Kinase Inhibitors / administration & dosage
-
Quality of Life
-
Receptor, Fibroblast Growth Factor, Type 1 / genetics*
-
Translocation, Genetic / genetics
Substances
-
CNTRL protein, human
-
Cell Cycle Proteins
-
Oncogene Proteins, Fusion
-
Protein Kinase Inhibitors
-
FGFR1 protein, human
-
Receptor, Fibroblast Growth Factor, Type 1
-
Dasatinib
Supplementary concepts
-
Myeloproliferative Syndrome, Transient